Published in Lancet Diabetes Endocrinol on December 23, 2013
The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int (2016) 2.91
Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. Clin Chem (2015) 1.52
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14
Treatment of severe hypertriglyceridaemia. Lancet Diabetes Endocrinol (2014) 1.08
Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia (2015) 0.96
Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes Metab J (2015) 0.94
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest (2016) 0.89
Diabetes Dyslipidemia. Diabetes Ther (2016) 0.85
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag (2016) 0.80
Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). Metabolism (2015) 0.80
Hypertriglyceridemia and Cardiovascular Diseases: Revisited. Korean Circ J (2016) 0.80
PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci (2016) 0.80
The year in cardiology 2015: prevention. Eur Heart J (2016) 0.79
Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes (2014) 0.79
Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J (2014) 0.79
Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis (2017) 0.79
The pathophysiology of intestinal lipoprotein production. Front Physiol (2015) 0.77
Analysis of risk factors and their interactions in type 2 diabetes mellitus: A cross-sectional survey in Guilin, China. J Diabetes Investig (2016) 0.77
Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants. Eur J Hum Genet (2015) 0.76
Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Curr Cardiol Rep (2016) 0.76
Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol (2017) 0.75
The interaction effects of risk factors for hypertension in adults: a cross-sectional survey in Guilin, China. BMC Cardiovasc Disord (2016) 0.75
The Contribution of GWAS Loci in Familial Dyslipidemias. PLoS Genet (2016) 0.75
APOC3: Triglycerides do matter. Glob Cardiol Sci Pract (2014) 0.75
Treatment of severe hypertriglyceridaemia--authors' reply. Lancet Diabetes Endocrinol (2014) 0.75
Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. Lipids Health Dis (2015) 0.75
Effects of a Plant Sterol or Stanol Enriched Mixed Meal on Postprandial Lipid Metabolism in Healthy Subjects. PLoS One (2016) 0.75
Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. Lipids Health Dis (2017) 0.75
Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia. J Lipid Res (2016) 0.75
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis (2016) 0.75
A 1-month-old infant with chylomicronemia due to GPIHBP1 gene mutation treated by plasmapheresis. Ann Pediatr Endocrinol Metab (2017) 0.75
PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol (2015) 0.75
Genetics of Triglycerides and the Risk of Atherosclerosis. Curr Atheroscler Rep (2017) 0.75
[Severe hypertriglyceridemia : Diagnostics and new treatment principles]. Internist (Berl) (2017) 0.75
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol (2017) 0.75
[Congenital disorders of lipoprotein metabolism]. Herz (2017) 0.75
Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study. Neurol Genet (2017) 0.75
T2DiACoD: A Gene Atlas of Type 2 Diabetes Mellitus Associated Complex Disorders. Sci Rep (2017) 0.75
Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis (2017) 0.75
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA (2007) 11.98
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA (2012) 9.37
An anatomically comprehensive atlas of the adult human brain transcriptome. Nature (2012) 7.46
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med (2010) 6.84
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation (2006) 6.17
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol (2012) 5.12
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet (2013) 3.87
Atherogenesis: a postprandial phenomenon. Circulation (1979) 3.74
Hypertriglyceridemia: its etiology, effects and treatment. CMAJ (2007) 3.42
Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA (2008) 3.10
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA. Circulation (1965) 2.85
Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet (2009) 2.80
Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med (2007) 2.52
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes (2011) 2.29
Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem (2010) 2.26
Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis (1989) 2.14
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol (2008) 2.10
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet (2011) 1.78
The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med (2011) 1.70
Genetic determinants of plasma triglycerides. J Lipid Res (2010) 1.63
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51
A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet (2009) 1.49
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J (2012) 1.36
Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol (2004) 1.31
Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol (1995) 1.25
Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl (2010) 1.22
Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis (2006) 1.21
Combination lipid therapy in type 2 diabetes. N Engl J Med (2010) 1.20
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis (2012) 1.19
Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can J Physiol Pharmacol (2009) 1.15
Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol (2011) 1.10
Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta (2011) 1.09
A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med (2001) 1.06
Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation (1997) 1.06
Triglycerides and coronary heart disease: have recent insights yielded conclusive answers? Curr Opin Lipidol (2009) 1.00
An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol (2011) 0.99
Fasting and nonfasting LDL cholesterol: to measure or calculate? Clin Chem (2009) 0.96
Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis (1998) 0.96
'Pseudohypertriglyceridemia' caused by hyperglycerolemia due to congenital enzyme deficiency. Clin Chim Acta (1982) 0.94
Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res (2002) 0.90
Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations. Arterioscler Thromb (1991) 0.88
Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis (1982) 0.87
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther (2010) 0.86
HDL--is it too big to fail? Nat Rev Endocrinol (2013) 0.86
Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol (2011) 0.85
Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta (2011) 0.83
Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ (2014) 4.69
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther (2016) 1.46
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J (2015) 1.28
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J (2017) 0.85
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
Acidification of the intimal fluid: the perfect storm for atherogenesis. J Lipid Res (2014) 0.81
Potential pathological roles for oxidized low-density lipoprotein and scavenger receptors SR-AI, CD36, and LOX-1 in aortic valve stenosis. Atherosclerosis (2014) 0.81
Marginal role for 53 common genetic variants in cardiovascular disease prediction. Heart (2016) 0.79
The impact of mast cells on cardiovascular diseases. Eur J Pharmacol (2015) 0.78
Enhanced vascular permeability facilitates entry of plasma HDL and promotes macrophage-reverse cholesterol transport from skin in mice. J Lipid Res (2014) 0.77
A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease. Atherosclerosis (2014) 0.77
Activated human mast cells induce LOX-1-specific scavenger receptor expression in human monocyte-derived macrophages. PLoS One (2014) 0.76
Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol (2016) 0.76
Spatial distributions of lipids in atherosclerosis of human coronary arteries studied by time-of-flight secondary ion mass spectrometry. Am J Pathol (2015) 0.76
Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition? Eur Heart J (2016) 0.76
Statistical vs clinical significance: a matter of debate for orlistat treatment. Pharmacol Res (2017) 0.75
HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. Prog Lipid Res (2017) 0.75
Life-threatening coronary disease is prevalent in patients with stenosing carotid artery disease. Int J Stroke (2015) 0.75
Genetic analysis of hyperemesis gravidarum reveals association with intracellular calcium release channel (RYR2). Mol Cell Endocrinol (2016) 0.75
Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities. J Clin Lipidol (2016) 0.75
HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions. Drug Discov Today (2017) 0.75
Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res (2017) 0.75
Combination of intracerebral haemorrhage and familial hypercholesterolemia in the acute hospital setting--a challenge for statin treatment? Int J Stroke (2015) 0.75
Phytosterol-mediated inhibition of intestinal cholesterol absorption in mice is independent of liver X receptor. Mol Nutr Food Res (2017) 0.75